Allogene Therapeutics, Inc. — Director's Dealing 2021

May 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-05-24

Reporting Person: Belldegrun Arie (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-24	Common Stock	M	379066	$18.22	Acquired	583034	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-24	Stock Option (Right to Buy)	$18.22	M	379066	Disposed	2030-03-18	Common Stock (379066)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	40000	Indirect
Common Stock	1798163	Indirect
Common Stock	788990	Indirect
Common Stock	3710006	Indirect

Footnotes

F1: The securities are held in the name of Bellco Legacy LLC (Bellco Legacy). Bellco Legacy is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.

F2: The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3: The securities are held in the name of Bellco Capital LLC, of which the reporting person is the manager.

F4: The securities are held in the name of the Belldegrun Family Trust.

F5: 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter.